Effects Of Gong's Versus Mulligan Mobilization In Patients With Adhesive Capsulitis

November 12, 2024 updated by: Riphah International University

Effects Of Gong's Versus Mulligan Mobilization On Pain, Range Of Motion, Functional Disability and Quality Of Life In Patients With Adhesive Capsulitis

A Randomized Clinical Trial will be conducted at DHQ hospital kasur,BIT hospital kasur,Arif memorial hospital Lahore.Pre-diagnosed patients will be reassessed by applying (Shoulder Shrug Sign, Hand to neck, Hand to scapula, Hand to opposite scapula,Hand to back,Capsular pattern movement restriction)Plus all other special tests will be applied to confirm that symptoms are not due to other shoulder pathologies but are due to just adhesive capsulitis then through consecutive sampling technique on 60 patients they will be allocated using computer generated sampling(random number table) into Group A and Group B.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A Randomized Clinical Trial will be conducted at DHQ hospital kasur,BIT hospital kasur,Arif memorial hospital Lahore.Pre-diagnosed patients will be reassessed by applying (Shoulder Shrug Sign, Hand to neck, Hand to scapula, Hand to opposite scapula,Hand to back,Capsular pattern movement restriction)Plus all other special tests will be applied to confirm that symptoms are not due to other shoulder pathologies but are due to just adhesive capsulitis then through consecutive sampling technique on 60 patients they will be allocated using computer generated sampling(random number table) into Group A and Group B. Group A will be treated with Gong's mobilization and Group B will be treated with Mulligan MWM The procedures will be performed Three sets of 10 repetitions, with 1 minute rest between sets,thrice per week for a total of six weeks. Pre and post intervention values will be taken on 1st day and after 6 weeks. Outcome measures will be conducted through VAS for pain,SPADI for functional disability , goniometer for range of motion ,SF-36 for quality of life after 6 weeks. Data will be analyzed during SPSS software version 25. After assessing normality of data by Shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan
        • Recruiting
        • Iffat Anwar Medical Complex
        • Contact:
        • Principal Investigator:
          • Adeena Nisar, DPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 40 to 50 years
  • Both male and female
  • Pre-diagnosed Unilateral Primary Frozen shoulder patients
  • Prediagnosed Stage 3(Frozen phase) patients(27)

Exclusion Criteria:

  • Patients with previous surgery in the shoulder joint
  • History of recent fracture or severe trauma to the shoulder
  • Diagnosed instability or previous history of dislocation
  • Systemic inflammatory conditions(e.g.rheumatoid arthritis)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Gong's Technique Group
The subject will sat on knee-high chair with the spine in a neutral position and comfortably extends both their arms. Therapist will stand on the side opposite to the affected side. The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand. Simultaneously, the subject will quickly and powerfully perform shoulder abduction with elbow flexion and with palm facing inside and the back of the hand facing outside. During this time, the hands of the therapist kept facing the humeral head with long axis of the palm along with the long axis of the humerus. The therapist followed the subject performing shoulder abduction, at the same speed while maintaining a little distraction, and adding acceleration in the end range.
Other: Gong's Mobilization Technique
The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.
Experimental: Mulligan Mobilization
For shoulder abduction, therapist applied a posterolateral gliding force over the head of the humerus, while patient actively abducted his arm. For shoulder flexion, the therapist applied a posterolateral glide as patient flexed his shoulder. For shoulder internal rotation, therapist applied an inferior shoulder glide and stabilized the scapula as the patient internally rotated his shoulder, and adducted his upper arm. As the therapist pushed the shoulder into adduction in this way, the head of the humerus was distracted laterally. Therapist hand in the axilla acted as a fulcrum.For shoulder external rotation,therapist applied posterolateral glide in sitting position
Other: Mulligan Mobilization Technique
Mulligan Mobilization Technique

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Range of Motion
Time Frame: Pre & Post 6 weeks
Goniometer
Pre & Post 6 weeks
Level of Pain
Time Frame: Pre & Post 6 weeks
Numeric Pain Rating Scale
Pre & Post 6 weeks
Functional Disability
Time Frame: Pre & Post 6 weeks
Shoulder Pain and Disability Index
Pre & Post 6 weeks
Quality of Life Level
Time Frame: Pre & Post 6 weeks
Sort Form Survey-36
Pre & Post 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Muhammad Hassan, MSPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 24, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 24, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 24, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 12, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 12, 2024

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 13, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 13, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 12, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/24/0116

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings